---
mi_id: MIPR-node_f36bede
type: press_release
canonical_url: "https://www.pheonixresearch.com/healthcare/veterinary-healthcare/press-release/veterinary-point-of-care-diagnostics-market-to-reach-usd-5-92-billion-by-2033/"
md_url: "https://www.pheonixresearch.com/healthcare/veterinary-healthcare/press-release/veterinary-point-of-care-diagnostics-market-to-reach-usd-5-92-billion-by-2033.md"

schema:
  "@type": NewsArticle
  "@id": MIPR-node_f36bede
  url: "https://www.pheonixresearch.com/healthcare/veterinary-healthcare/press-release/veterinary-point-of-care-diagnostics-market-to-reach-usd-5-92-billion-by-2033/"
  title: "Veterinary Point-of-Care Diagnostics Market to Reach USD 5.92 Billion by 2033 as In-Clinic Consumables Carry 97.5% of Growth"
  description: "Market at USD 3,150.0mn in 2025 rising to USD 5,922.9mn by 2033 at 8.21%. In-clinic consumables grow 10.20% and carry 97.5% of growth while rapid lateral-flow assays grow 1.00%. No premarket clearance is required for animal devices."
  datePublished: "2026-11-21T12:54:28+00:00"
  dateModified: "2026-11-21T12:54:37+00:00"
  keywords:
    - veterinary point-of-care diagnostics market
    - rapid animal diagnostics
    - IDEXX VetLab consumables
    - reference interval
    - veterinary diagnostics regulation
    - market forecast 2033
  isPartOf:
    - id: MISG-node_620b0a5
      type: CollectionPage
      url: "https://www.pheonixresearch.com/healthcare/veterinary-healthcare/"
      name: Veterinary Healthcare
    - id: MIIN-node_50b4dbf
      type: CollectionPage
      url: "https://www.pheonixresearch.com/healthcare/"
      name: Healthcare
    - id: MIWS-root
      type: WebSite
      url: "https://www.pheonixresearch.com/"
      name: Pheonix Research

acf:
  phoenix_meta_title: Veterinary Point-of-Care Diagnostics Market to Reach USD 5.92 Billion by 2033
  phoenix_meta_description: "Market at USD 3,150.0mn in 2025 rising to USD 5,922.9mn by 2033 at 8.21%. In-clinic consumables grow 10.20% and carry 97.5% of growth while rapid lateral-flow assays grow 1.00%. No premarket clearance is required for animal devices."

global_schema:
  organization:
    "@id": MIWS-root#organization
    "@type": Organization
    url: "https://www.pheonixresearch.com/"
    name: Pheonix Research
  website:
    "@id": MIWS-root
    "@type": WebSite
    url: "https://www.pheonixresearch.com/"
    name: Pheonix Research
  api:
    "@id": MIWS-root#api
    "@type": WebAPI
    url: "https://www.pheonixresearch.com/"

graph:
  node_id: MIPR-node_f36bede
  graph_node_endpoint: "https://graph.pheonixresearch.com/api/v1/query/live/node/MIPR-node_f36bede"
  graph_snapshot: "https://graph.pheonixresearch.com/api/v1/read/live/graph"
  graph_exclusions: "https://graph.pheonixresearch.com/api/v1/read/live/exclusions"
  graph_meta: "https://graph.pheonixresearch.com/api/v1/read/live/meta"
  graph_bundle: "https://graph.pheonixresearch.com/api/v1/read/live/bundle"

discovery:
  discovery_json: "https://www.pheonixresearch.com/.well-known/pheonix-discovery.json"
  llms_txt: "https://www.pheonixresearch.com/llms.txt"
  sitemap: "https://www.pheonixresearch.com/sitemap.xml"
---
# Veterinary Point-of-Care Diagnostics Market to Reach USD 5.92 Billion by 2033 as In-Clinic Consumables Carry 97.5% of Growth

**LONDON, 21 November 2026** — The global veterinary point-of-care and rapid animal diagnostics market is valued at USD 3,150.0 million in 2025 and is forecast to reach USD 5,922.9 million by 2033, a compound annual growth rate of 8.21 per cent, according to a new market report published by Pheonix Research.

The report finds that the category is not a single market growing at a single rate, but two layers moving in opposite directions. Instrument-attached consumables — the chemistry, haematology, immunoassay and blood-gas reagents that run only inside a specific manufacturer's analyser — are valued at USD 2,300.0 million in 2025 and reach USD 5,002.4 million in 2033 at 10.20 per cent. Rapid lateral-flow assays, the self-contained strip tests the word "rapid" in the category name refers to, are valued at USD 850.0 million and reach USD 920.4 million at 1.00 per cent.

Of the USD 2,772.9 million the market adds between 2025 and 2033, USD 2,702.4 million — 97.5 per cent — comes from the consumables layer. The rapid-test layer adds USD 70.4 million.

### The split is disclosed, not inferred

Pheonix Research's finding is corroborated line by line in the full-year 2025 results of IDEXX Laboratories, the largest supplier in the market. IDEXX reports VetLab in-clinic consumables up 13.7 per cent organic, diagnostics capital instruments up 49.3 per cent organic, reference laboratory services up 5.9 per cent organic, and rapid assay products *down* 3.3 per cent organic. Premium instrument installed base grew 12 per cent.

"The most valuable company in this category is placing nearly half again as many analysers, filling them with reagents growing at double digits, and watching its strip tests shrink," the report states. "That is not a demand failure. It is a form-factor failure. A strip carries no platform, so it carries no switching cost, and what is left is price."

### No regulator requires clearance, and the regulator says so

The report attributes the durability of the consumables layer to a regulatory absence rather than to assay performance. The US Food and Drug Administration states that it "does not require submission of a 510(k), PMA, or any pre-market approval for devices intended for animal use," and that manufacturers of animal devices are exempt from establishment registration, device listing and post-marketing reporting.

The USDA's Center for Veterinary Biologics licenses a subset of veterinary diagnostics, but its Veterinary Services Memorandum 800.73, reissued 12 January 2024, states that the Center "does not have regulatory jurisdiction over some diagnostics such as serum chemistries, metabolic diseases, or hormone level test kits." The same memorandum declines jurisdiction over tests that report a general disease result without characterising the organism to genus or family, citing by name a mastitis test reporting "gram positive" or "coliform" bacteria. A peer-reviewed comparative review published by the World Organisation for Animal Health found the position ranges from no regulation in the European Union to oversight in Japan comparable to the regime for human in vitro diagnostics.

The consequence, the report argues, is that the reference interval — the range against which a result is judged normal or abnormal — is proprietary to the analyser that produced it and is not transferable to a rival platform. That creates a switching cost which is administrative and clinical rather than financial.

### Lock-in protects volume, not price

Notably, the report finds that this switching cost does not translate into pricing power. Of the growth, USD 2,010.0 million (72.5 per cent) is more tests and USD 762.9 million (27.5 per cent) is a dearer test. Realised revenue per test rises only from USD 12.00 to USD 13.77, a CAGR of 1.74 per cent, while test volume rises from 262.5 million to 430.0 million at 6.36 per cent.

"The moat defends volume, not price," the report states. "A competitor cannot win by being cheaper, because a cheaper result is not comparable with the patient's history. So the incumbent does not need to raise the price. It only needs to keep the box."

### Reconciliation with the parent market

Point-of-care diagnostics at 8.21 per cent sits above total veterinary care, which Pheonix Research models at 6.70 per cent, and above reference laboratory testing, which grew 5.9 per cent organic at the market leader. The report attributes this ordering to expansion rather than substitution: both halves of the in-clinic and central-laboratory boundary grew in the same year, indicating that point-of-care testing functions as a triage layer that generates referrals to the reference laboratory rather than a substitute for it.

### Notes to editors

The value base is a construct. Only one supplier discloses point-of-care revenue at this granularity, so the 2025 point is built from IDEXX's disclosed point-of-care-attributable revenue of USD 2,046.0 million at an estimated 65 per cent share of the global market. The defensible band is USD 2.80 billion to 3.55 billion. The report publishes three sensitivities rather than a single point estimate, and refuses to publish a market-share table for any supplier other than the market leader, a regional split, or a transaction multiple — each because the evidence to support it does not exist.

The full report, *Global Veterinary Point-of-Care and Rapid Animal Diagnostics Market Report, Size, Share and Forecast 2026-2033*, is available from Pheonix Research. It contains six chapters, fifteen table-of-contents entries, four original data visualisations and ten company profiles with resolved Wikidata entity identifiers.

**About Pheonix Research**

Pheonix Research publishes market intelligence combining secondary research from filings, regulators and standards bodies with primary value-chain, boundary and pricing-architecture analysis.

**Media contact:** Pheonix Research, via the contact form at pheonixresearch.com.
